[{"id":"7e70ebdc-cdaa-4580-9eb1-432961d43354","acronym":"CAMBRIA-2","url":"https://clinicaltrials.gov/study/NCT05952557","created_at":"2023-07-20T14:08:53.643Z","updated_at":"2025-02-25T14:18:07.526Z","phase":"Phase 3","brief_title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","source_id_and_acronym":"NCT05952557 - CAMBRIA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 5500","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 03/04/2030","primary_completion_date":" 03/04/2030","study_txt":" Completion: 05/06/2037","study_completion_date":" 05/06/2037","last_update_posted":"2025-02-18"},{"id":"10294ca2-7f84-44ce-af11-76cdd03b1746","acronym":"SERENA-2","url":"https://clinicaltrials.gov/study/NCT04214288","created_at":"2021-01-18T20:31:16.451Z","updated_at":"2025-02-25T14:40:27.343Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04214288 - SERENA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 04/22/2020","start_date":" 04/22/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-14"},{"id":"89c18e67-5d9f-4f4c-836e-d176238b546e","acronym":"CAMBRIA-1","url":"https://clinicaltrials.gov/study/NCT05774951","created_at":"2023-03-20T20:03:21.727Z","updated_at":"2025-02-25T15:20:21.062Z","phase":"Phase 3","brief_title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","source_id_and_acronym":"NCT05774951 - CAMBRIA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 4300","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 04/20/2027","primary_completion_date":" 04/20/2027","study_txt":" Completion: 05/29/2036","study_completion_date":" 05/29/2036","last_update_posted":"2025-02-11"},{"id":"cce3783a-1b27-4829-a8df-f2ffd2039cf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541433","created_at":"2021-01-18T21:43:43.429Z","updated_at":"2024-07-02T16:34:37.966Z","phase":"Phase 1","brief_title":"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT04541433","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"8637b136-3de4-40fa-8293-aa26c472595a","acronym":"SERENA-6","url":"https://clinicaltrials.gov/study/NCT04964934","created_at":"2021-07-16T13:53:17.689Z","updated_at":"2024-07-02T16:34:59.080Z","phase":"Phase 3","brief_title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","source_id_and_acronym":"NCT04964934 - SERENA-6","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-06-04"},{"id":"98e502e8-5543-4a22-8deb-85c97dc8a17b","acronym":"SERENA-4","url":"https://clinicaltrials.gov/study/NCT04711252","created_at":"2021-01-19T20:52:29.359Z","updated_at":"2024-07-02T16:35:12.931Z","phase":"Phase 3","brief_title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","source_id_and_acronym":"NCT04711252 - SERENA-4","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • anastrozole • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1370","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 08/24/2026","primary_completion_date":" 08/24/2026","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-03-26"},{"id":"35555a3a-c45f-4001-9f3f-587dd24c1ab1","acronym":"SERENA-1","url":"https://clinicaltrials.gov/study/NCT03616587","created_at":"2021-01-17T17:55:38.542Z","updated_at":"2024-07-02T16:35:16.432Z","phase":"Phase 1","brief_title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","source_id_and_acronym":"NCT03616587 - SERENA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • anastrozole • camizestrant (AZD9833)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 396","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 07/10/2024","primary_completion_date":" 07/10/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-05"},{"id":"1f9fd67f-b6ed-42da-be1b-053fad842778","acronym":"AZD9833","url":"https://clinicaltrials.gov/study/NCT04818632","created_at":"2021-03-26T14:52:30.339Z","updated_at":"2024-07-02T16:35:34.893Z","phase":"Phase 1","brief_title":"AZD9833 China PK Study","source_id_and_acronym":"NCT04818632 - AZD9833","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • camizestrant (AZD9833)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/07/2023","primary_completion_date":" 09/07/2023","study_txt":" Completion: 09/07/2023","study_completion_date":" 09/07/2023","last_update_posted":"2023-10-03"},{"id":"77d54b5c-14c8-4b4d-a137-51c9737d72d0","acronym":"SERENA-3","url":"https://clinicaltrials.gov/study/NCT04588298","created_at":"2021-01-18T21:53:11.603Z","updated_at":"2024-07-02T16:35:41.061Z","phase":"Phase 2","brief_title":"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer","source_id_and_acronym":"NCT04588298 - SERENA-3","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • camizestrant (AZD9833)"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 11/02/2020","start_date":" 11/02/2020","primary_txt":" Primary completion: 06/19/2023","primary_completion_date":" 06/19/2023","study_txt":" Completion: 06/19/2023","study_completion_date":" 06/19/2023","last_update_posted":"2023-08-03"}]